MLTX peer analysis
MoonLake (MLTX) against its competitors: price, today's move, 1-year return and market value side by side.
MLTX and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ACRS Aclaris Therapeutics | $3.90 | 8.03% | 59.73% | $504.77M |
| ALMS Alumis | $6.03 | 3.08% | 31.51% | – |
| ANAB AnaptysBio | $45.80 | 0.48% | 29.08% | $1.39B |
| ATTO Attovia Therapeutics | $15.27 | 1.80% | – | $694.81M |
| CNTB Connect Biopharma | $0.73 | -6.25% | -56.58% | – |
| DNTH Dianthus Therapeutics | $88.00 | 6.01% | 155.68% | – |
| EQ Equillium | $1.33 | -5.00% | 5.56% | $84.33M |
| NRIX Nurix Therapeutics | $15.07 | 1.55% | 23.48% | – |
| ORKA Oruka Therapeutics | $103.90 | 8.21% | 276.35% | – |
| ZURA Zura Bio | $4.07 | 9.41% | 12.12% | – |
| MLTX MoonLake | $11.60 | 7.41% | 9.07% | – |
- MLTX's peers: ACRS (Aclaris Therapeutics), ALMS (Alumis), ANAB (AnaptysBio), ATTO (Attovia Therapeutics), CNTB (Connect Biopharma), DNTH (Dianthus Therapeutics), EQ (Equillium), NRIX (Nurix Therapeutics).
Updated 2026-11-07 11:54 UTC